Aspargo Laboratories Inc. Announces Completion of Dosing of All Subjects in Sildenafil Oral Suspension Bioavailability Study and Initiation of Dosing in Companion Food-Effect Study
December 05, 2023 08:00 ET
|
Aspargo Laboratories, Inc.
Dosing complete for 53 subjects in Sildenafil Oral Suspension Bioavailability StudyInitiated dosing in 38 subjects in Sildenafil Oral Suspension Food-Effect StudyTop-line data from both studies...
Aspargo Laboratories Inc. Announces Initial Dosing of All Subjects in Bioavailability Study for Sildenafil Oral Suspension
September 19, 2023 08:00 ET
|
Aspargo Laboratories, Inc.
Study will compare bioavailability of Sildenafil Oral Suspension and Viagra® tablets under fasted conditionsCompanion study will evaluate the effects of food on the bioavailability of Sildenafil Oral...
Aspargo Laboratories Announces IND Clearance by U.S. FDA, Enabling Launch of Bioequivalence and Food-Effect Studies for Sildenafil Oral Spray
September 05, 2023 08:00 ET
|
Aspargo Laboratories, Inc.
Company plans to initiate clinical trials in September 2023 to compare Sildenafil Oral Spray to Viagra® tablets, and effect of dose administration under fasted versus fed conditionsRepresents...
Aspargo Laboratories, Inc. Announces Filing of Its Investigational New Drug Application for Sildenafil Oral Spray
August 01, 2023 08:00 ET
|
Aspargo Laboratories, Inc.
Planned bioequivalence study in healthy adult male subjects will compare the rate and extent of absorption of ASP-001 (Sildenafil Oral Spray) versus Viagra® tabletsCompanion food-effect study will...
Aspargo Receives Regulatory Approval to Market Sildenafil Spray in Germany, Ireland, and The Netherlands
January 24, 2023 08:00 ET
|
Aspargo Laboratories, Inc.
The aggregate German, Irish and Dutch market for erectile dysfunction (ED) market exceeds $175 millionAspargo plans to launch Sildenafil Spray in Germany, Ireland, and the Netherlands under the...
Aspargo Extends Latin America Reach From Mexico to Argentina
November 29, 2022 08:00 ET
|
Aspargo Laboratories, Inc.
Aspargo Laboratories, Inc. to leverage Laboratorio SIDUS’ ED market position to launch Sildenafil Oral Spray in Argentina via exclusive License and Supply AgreementsAspargo’s Sildenafil Oral Spray...
Aspargo’s Global Footprint Grows With Middle East Expansion, Disrupting the Erectile Dysfunction Market With Oral Spray
October 04, 2022 08:00 ET
|
Aspargo Laboratories, Inc.
Aspargo Laboratories, Inc. and Taiba Healthcare Group to launch Sildenafil Spray in Middle East region via exclusive license and supply agreements Men in Saudi Arabia, Kuwait, the United Arab...
Aspargo Expands Beyond Spain Into Latin America, Disrupting Erectile Dysfunction (ED) Market With Oral Spray
June 21, 2022 08:03 ET
|
Aspargo Laboratories, Inc.
Aspargo Laboratories, Inc. and Laboratorios Vanquish, S.A. to jointly launch Sildenafil Oral Spray in Mexico via exclusive License and Distribution AgreementsMexico, Brazil, Argentina, and Columbia...
Aspargo Acquires Bandol® Sildenafil Spray, Currently Marketed In Spain
May 04, 2022 08:00 ET
|
Aspargo Laboratories, Inc.
Immediate revenue and expansion of global footprint Acquisition transforms Aspargo into a revenue producing company European market entry positions Aspargo for commercialization of Sildenafil Oral...
Aspargo Laboratories, Inc. Acquires International Rights to Sildenafil Oral Spray for the Treatment of Erectile Dysfunction
September 29, 2020 08:02 ET
|
Aspargo Laboratories, Inc.
Acquisition significantly boosts Aspargo’s presence as a global biopharmaceutical company in erectile dysfunction Company acquires international rights to Sildenafil Oral Spray from Farmalider, S.A....